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Editorial on the Research Topic
The CB2 Cannabinoid System: A New Strategy in Neurodegenerative Disorder and
Neuroinflammation
The cannabinoid receptors subtype 2 (CB2R) are emerging as novel targets for the development
of new therapeutic approaches and PET probes useful to early diagnose neuroinflammation as first
step in several neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson disease
(PD). Differently from the CB1 subtype (CB1R) present in the CNS where it modulates several
functions (memory, cognition, emotion, and pain control), CB2R ismainly localized in the immune
system (macrophages) and are overexpressed in microglia in response to neuroinflammation. Two
microglial activation states, M1 and M2, are widely reported. The M1 state (neurotoxic state)
is characterized by the release of pro-inflammatory factors (such as IL-1B, IL-18, and IL-6 and
inducible nitric oxide synthase) while the M2 state (neuroprotective state) is associated to the
release of anti-inflammatory factors (IL-10, IL-4, andNGF). CB2R plays a pivotal role inmicroglial-
derived neuroinflammation, since modulates cell proliferation, migration, and differentiation into
M1 or M2 phenotypes (Mecha et al., 2015).
This Research Topic is mainly focused on the involvment of CB2R in neurodegenerative
disorders and on the usefulness of CB2R ligands in the therapy and early diagnosis of
neuroinflammation as onset of neurodegeneration.
In the reviews of Aso and Ferrer and Cassano et al. an interesting and exaustive overview of the
endogenous cannabinoid signaling and its role in neuroinflammation and neurogenesis is reported.
The potential of CB2R as therapeutic target in AD is argued by several evidences derived by robust
experimental models and the effects modulated by CB2R agonists on different pathways involved
in the pathogenesis of AD are discussed; indeed, these ligands are able to reduce inflammation,
Aβ production and deposition, tau protein hyper-phosphorylation and oxidative stress damage
caused by Aβ peptides. CB2R agonists are also able to induce Aβ clearance leading to cognitive
improvement in AD models.
Javed et al. focused their study on the neuroprotective effect of β-caryophyllene (BCP), a
natural CB2R agonist, in a rotenone (ROT)-induced animal model of PD. In their paper, the
authors reported the beneficial neuroprotective effect due to BCP activity against ROT-induced
neurodegeneration; the observed beneficial effects has been linked to CB2R activation since
the administration of the CB2R antagonist AM630 was able to decrease the neuroprotective
effects of BCP.
Navarro-Dorado et al. in their research article deepened the beneficial effects of CBR ligands in
AD-type pathology studying the effects of the CB1/CB2 mixed agonist WIN 55,212-2 and the CB2
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selective agonist JWH-133 on the vessel density in amyloid
precursor protein (APP) transgenic mice, line 2,576, observing
an improvment of the vascular responses.
Navarro et al. considered the localization of the CB2R
subtype in specific cell types (activated astrocytes, reactive
microglia, perivascular microglia, oligodendrocytes, and neural
progenitor cells) and structures (blood-brain barrier) pivotal
for the maintenance of the CNS integrity; moreover, they
underlined the challenges faced in the CB2R-based drug design
for the development of CB2R PET probes and for an innovative
therapeutic strategy for neurodegeneration. Therefore, the
authors reported an overview of the CB2R ligands planned
as therapeutic and diagnostic agents in CNS diseases. In
the diagnostic field, starting from the first PET radiotracer
developed to image CB2R aspect, [11C]-NE40, the structural
optimization performed with the aim to improve the brain
penetration and to decrease the non-specific binding of these
CB2R probes has been reported. The authors identified a
18F-triazine scaffold as a promising PET tracer candidate for
the in vivo evaluation of inflammation. In the therapeutic
field, the authors showed the findings reported by CB2R
agonists in in vitro (BV-2 microglial cell line and in primary
culture of microglia) and in vivo models (murine model) of
neurodegeneration establishing a direct link between CB2R-
targeting and neuroprotecion. Despite the increasing number
of CB2R ligands developed, few synthetic CB2R agonists
have reached clinical trials; the CB2R agonists GW842166X,
CP55940, S-777469, and JTE-907 completed phase II for
the pain therapy but none of them has been used in
neurodegenerative diseases. However, the in vitro and in
vivo studies performed led to several scaffolds useful to the
development of CB2R ligands able to exert neuroprotection and
neurorestoration.
Bu et al. shed light on a new scenario in neurodegenerative
diseases since suggests a new therapeutic approach by the use
of CB2R inverse agonists. Indeed, in their research article the
authors deepened their previous work focused on the pivotal
role of the CB2R inverse agonist, SMM-189, on neuroprotection,
demonstrating the ability of SMM-189 to act on brain microglia
converting it to the beneficial M2 state leading to neurons
rescue in cortex, striatum, and amygdala. Therefore, not only
CB2R agonists but also CB2R inverse agonists could be an
useful strategy to face neuroinflammation in neurodegeneration;
the difference between the two CB2R profiles (agonist and
inverse agonist) is that the treatment with a CB2R agonist
decreases M1 activation but do not induce M2 activation
state.
Ahamed et al. and Haider et al. reported the development of
PET-imaging agents to target CB2R: [11C]MA2 and [18F]MA3
and [11C]AAT-015 and [11C]AAT-778.
The first two probes are 11C- and 18F- radiolabelled analogs
of the highly potent arylamide oxadiazole CB2 agonist. Both
the analogs displayed a good affinity toward the desired target
(CB2R), good radiochemical yield, high radiochemical purity,
and high specific activity. Both probes displayed good results in
vivo since displayed an efficient blood clearance and high brain
uptake. By contrast, the thiophene-based radiotracers [11C]AAT-
778 and [11 C]AAT-015 developed by Haider et al. failed in
vivo because of the lack of specificity for CB2R-positive spleen
tissue and thus the two tracers were not further evaluated in
neuroinflammatory animal models. However, the high CB2R
affinity and selectivity makes this class of compounds the starting
point for structural optimization to improve physicochemical
and pharmacological properties.
In conclusion, considering that neuroinflammation
has been widely reported as indicator and modulator of
neurodegeneration (Wyss-Coray and Mucke, 2002), the
reduction of the neuroinflammatory responses could be
considered as a new therapeutic strategy in these diseases.
Moreover, the selective CB2R overexpression on the activated-
microglial cells provides also a highly specialized target useful to
an early diagnosis of the neurodegenerative diseases.
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